搜索范围
Y0000377
应用筛选条件
关键词:'Y0000377'
显示 1-30 #N/A 196 条结果 关于 "Y0000377" 范围 论文
A J Khan et al.
Epidemiology and infection, 143(1), 71-80 (2014-03-20)
We conducted a case-control study involving 150 genotype 3 chronic hepatitis C virus (HCV) patients and 150 healthy controls to investigate the association of polymorphisms in the interleukin-10 (IL-10) gene with chronic HCV infection and the association of these polymorphic
Adam Isaiah Newman et al.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 27(4), 217-223 (2013-04-26)
The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in
Michael P Curry et al.
Gastroenterology, 148(1), 100-107 (2014-09-28)
Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence, but existing interferon-based regimens are poorly tolerated and are either ineffective or contraindicated
Ping Ji et al.
Biological & pharmaceutical bulletin, 38(1), 1-6 (2015-03-07)
The bark, leaves, and flowers of Paulownia trees have been used in traditional Chinese medicine to treat infectious and inflammatory diseases. We investigated the antiviral effects of Paulownia tomentosa flowers, an herbal medicine used in some provinces of P. R. China
Min Chen et al.
Journal of natural products, 77(12), 2720-2724 (2014-11-25)
Two new prenylated dihydroquinolone derivatives, 22-O-(N-Me-l-valyl)aflaquinolone B (1) and 22-O-(N-Me-l-valyl)-21-epi-aflaquinolone B (2), and two known analogues, aflaquinolones A (3) and D (or a diastereomer of D, 4), were isolated from the mycelia of a gorgonian-derived Aspergillus sp. fungus. The structures
[Therapy of chronic hepatitis C].
Stella Schaffstein et al.
Praxis, 103(8), 423-436 (2014-04-10)
Stefan Zeuzem et al.
The New England journal of medicine, 370(17), 1604-1614 (2014-04-12)
In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267), dasabuvir (also known as ABT-333), and ribavirin for the retreatment of HCV in patients who
Cristina Novembrino et al.
Journal of viral hepatitis, 21(12), 944-949 (2014-07-22)
A cytoplasmic antigen associated to inosine-5'-monophosphatedehydrogenase 2 eliciting specific antibodies (antirods and rings, RR) has been identified in patients with chronic hepatitis C who were exposed to pegylated interferon (PI) and ribavirin (RBV). The significance of anti-RR in these patients
Jingyin Dong et al.
Immunopharmacology and immunotoxicology, 36(6), 412-419 (2014-09-26)
Elevation of myeloid-derived suppressor cells (MDSCs) was observed in some viral infectious diseases. In this study, we studied whether ribavirin, a widely used clinical antiviral drug, could impact the differentiation of human MDSCs in vitro. Flow cytometric analysis showed that
Ira M Jacobson et al.
Lancet (London, England), 384(9941), 403-413 (2014-06-08)
Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens
Emanuela Fabiola Craparo et al.
Journal of biomedical nanotechnology, 9(6), 1107-1122 (2013-07-19)
In this paper, we describe the preparation of liver-targeted nanoparticles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors in the liver (i.e., ASGPR in hepatocytes). These particles were obtained starting from a
Simone Susser et al.
PloS one, 9(11), e112592-e112592 (2014-11-14)
IL28B gene polymorphism is the best baseline predictor of response to interferon alfa-based antiviral therapies in chronic hepatitis C. Recently, a new IFN-L4 polymorphism was identified as first potential functional variant for induction of IL28B expression. Individualization of interferon alfa-based
Badr Al-Bawardy et al.
Mayo Clinic proceedings, 89(5), 595-601 (2014-03-26)
To examine the effectiveness and tolerability of triple therapy with pegylated interferon (p-IFN), ribavirin (RBV), and telaprevir in patients with chronic hepatitis C receiving treatment in an academic practice setting and in a more clinically diverse population compared with patients
N V Fedoseeva et al.
Zhurnal mikrobiologii, epidemiologii, i immunobiologii, (3)(3), 97-103 (2013-09-05)
Various macroorganism factors influence spontaneous and therapy induced elimination of hepatitis C virus. Standard therapy is application of a combination of pegylated interfernos and ribavirin. However such tactics results in attainment of a resistant virological response in approximately half the
S Akamatsu et al.
Journal of viral hepatitis, 22(2), 166-174 (2014-06-17)
Treatment success of chronic hepatitis C virus genotype 1 infection has improved with the advent of telaprevir plus peg-interferon/ribavirin triple combination therapy. However, the effect of inosine triphosphatase (ITPA) polymorphism on dose reduction during triple therapy, especially during the postmarketing
Linda E Muñoz-Espinosa et al.
Archives of medical research, 44(6), 444-448 (2013-09-21)
We undertook this study to evaluate the virological response to and presence of adverse events to natural interferon α (nIFNα; Multiferon®) treatment in previously nonresponsive Mexican patients chronically infected with genotype 1 hepatitis C. Thirty-nine patients received a 4-week induction
Katerina Tsilika et al.
JAMA dermatology, 149(6), 675-677 (2013-04-05)
Interferon alfa remains the central treatment for chronic hepatitis C virus (HCV) infection. Cases of cutaneous and mucous hyperpigmentations during interferon alfa treatment have been reported, but they are considered rare adverse effects. To study the clinical presentation and frequency
Shaimuna Fareeha Sajjad et al.
JPMA. The Journal of the Pakistan Medical Association, 62(11), 1229-1232 (2013-07-23)
Recommended treatment of chronic Hepatitis C virus (HCV) infection is interferon and ribavirin. Most patients develop side effects during treatment. Weight loss is one of the side effects of interferon therapy. Present study was conducted at Pakistan Medical and Research
Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
S E Congly et al.
Alimentary pharmacology & therapeutics, 40(8), 983-984 (2014-09-18)
Guido Stirnimann
Expert opinion on pharmacotherapy, 15(17), 2609-2622 (2014-10-28)
Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in
Michael Manns et al.
Lancet (London, England), 384(9941), 414-426 (2014-06-08)
Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained virological response can be suboptimum in patients with HCV genotype 1 infection. The efficacy
J P Bilello et al.
Antimicrobial agents and chemotherapy, 58(8), 4431-4442 (2014-05-29)
The hepatitis C virus (HCV) nonstructural 5A (NS5A) protein is a clinically validated target for drugs designed to treat chronic HCV infection. This study evaluated the in vitro activity, selectivity, and resistance profile of a novel anti-HCV compound, samatasvir (IDX719)
Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection.
Michael S Saag
JAMA, 312(4), 347-348 (2014-07-20)
Hiba Ahmad Zahreddine et al.
Nature, 511(7507), 90-93 (2014-05-30)
Drug resistance is a major hurdle in oncology. Responses of acute myeloid leukaemia (AML) patients to cytarabine (Ara-C)-based therapies are often short lived with a median overall survival of months. Therapies are under development to improve outcomes and include targeting
Liwei An et al.
Antiviral research, 109, 54-63 (2014-06-28)
Infection with influenza A virus is still a global concern since it causes significant mortality, morbidity and economic loss. New burst pandemics and rapid emergence of drug-resistance strains in recent years call for novel antiviral therapies. One promising way to
Irina C Albulescu et al.
The Journal of general virology, 95(Pt 12), 2683-2692 (2014-08-20)
Chikungunya virus (CHIKV) is a re-emerging mosquito-borne alphavirus that causes severe persistent arthralgia. To better understand the molecular details of CHIKV RNA synthesis and the mode of action of inhibitors, we have developed an in vitro assay to study CHIKV
Michael Köhler et al.
BMJ (Clinical research ed.), 350, h796-h796 (2015-02-28)
When a new drug becomes available, patients and doctors require information on its benefits and harms. In 2011, Germany introduced the early benefit assessment of new drugs through the act on the reform of the market for medicinal products (AMNOG).
Susanne Sarkar et al.
The British journal of psychiatry : the journal of mental science, 206(1), 45-51 (2014-11-02)
Antiviral therapy with interferon-alpha (IFN-α) for hepatitis C virus (HCV) infection is associated with increased risk for depression. To identify clinical predictors for IFN-α-induced depression during antiviral therapy for HCV infection. Depression (defined with the Montgomery-Åsberg Depression Rating Scale (MADRS))
Tao Meng et al.
Journal of virology, 88(10), 5803-5815 (2014-03-14)
In a screen for ribavirin resistance, a novel high-fidelity variant of human enterovirus 71 (EV71) with the single amino acid change L123F in its RNA-dependent RNA polymerase (RdRp or 3D) was identified. Based on the crystal structure of EV71 RdRp
Luke S Uebelhoer et al.
Antiviral research, 106, 86-94 (2014-04-10)
Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant challenge to global public health. Currently, no licensed therapies exist to treat filovirus infections, which cause up to 90% mortality in human cases. To facilitate
1/7